Moderna's stock plunged on Thursday, startling investors. But the company remains one of this year’s hottest biotech ...
Moderna gave investors a scare as its stock plunged on Thursday. But it's still one of the hottest biotechs this year. And it's hardly alone – the sector is on a roll and looks poised for more gains.
Even after its latest sharp fall, the drugmaker’s stock price assumes wild successes.
Moderna and Merck's personalized mRNA vaccine reduced melanoma recurrence/death risk by 42% in Phase 3 trials, but Moderna's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results